Global Ganja Report

Uruguay is still developing its nascent cannabis economy following the Christmas Eve signing of the new legalization law, but its leaders have already broached international exports. Diego Cánepa, media spokesman for President José Mujica, said that while development of the domestic market is the priority, representatives from countries including Israel, Canada and Chile have contacted Uruguay to inquire on importing prospects.  "It was not the law’s intention to regulate international trade of marijuana, but Uruguay is open and enthusiastic at the possibility," said Cánepa to Montevideo newspaper La Red 21 in comments picked up by International Business Times. Several private companies have even expressed interest in opening cannabis laboratories in Uruguay, he said. "It would be a challenge, if labs were to open installations in Uruguay," admitted Cánepa. "It goes beyond what the law previewed, but it would turn Uruguay into a biotechnology center. That is a huge step forward."

Medical marijuana advocates are telling President Barack Obama he has the power to reclassify cannabis after he said Jan. 31 it is up to Congress. In an exclusive CNN interview, Obama responded to a question about the federal cannabis classification by saying that, "what is and isn't a Schedule I narcotic is a job for Congress." Responded Steph Sherer, executive director of Americans for Safe Access (ASA): "President Obama just told the nation during his State of the Union address that because Congress has been unable to act, he would take executive action where he could on behalf of helping the American people,. The president has the authority to reclassify marijuana and could exercise that authority at any time."

New York Governor Andrew Cuomo announced during his State of the State address on Jan. 8 plans for a medical marijuana pilot program that would permit up to 20 hospitals to distribute cannabis to patients with serious illnesses. According to a press release, the pilot program "will allow qualified eligible participants to seek relief for their symptoms in a safe and legal manner, while also evaluating the effectiveness and feasibility of a medical marijuana system," with the findings of the program to help shape future policy. The plan creates the program within current New York statutory authority—specifically, the Controlled Substances Therapeutic Research Act of 1980, which allows the state to establish medical marijuana research programs in hospitals. Critics have claimed that the reliance on this statute is unworkable in the long-term. (Jurist, Jan. 9)

In an historic move, the American Herbal Pharmacopoeia (AHP) released the first installation of a two-part Cannabis Monograph (PDF) Dec. 10 that classifies marijuana as a botanical medicine, alongside many other widely accepted "Complementary and Alternative Medicines." Written and reviewed by leading experts, the monograph brings together an authoritative compendium of scientific data, including long-awaited standards for the plant's identity, purity, quality and properties. The monograph provides a foundation for health care professionals to integrate cannabis therapy into their practices on the basis of a full scientific understanding of the plant, its constituent components, and its biologic effects.

Moroccan lawmakers on Dec. 4 opened an unprecedented debate on legalizing medical and industrial uses of cannabis. The discussion of positive uses of cannabis cultivation "in creating an alternative economy" in Morocco, one of the world's top exporters, was convened following a campaign by dissident politicians.  "We are organizing a research day in parliament...on the use of medical kif, with Moroccan and international experts present," said Mehdi Bensaid, an MP with the Party of Authenticity and Modernity (PAM), adding that lawmakers are "looking at controlled rather than total legalization." Activists from Switzerland spoke about their country's experience with a recent decrim law at the session, which Bensaid called "the first step towards a draft law."

British firm GW Pharmaceuticals has won "orphan drug status"—a special category for agents developed to treat rare diseases—from the US Food and Drug Administration (FDA) for Epidiolex, a derivative of cannabidiol (CBD), to treat Dravet syndrome, a severe form epilepsy. In Utah, parents who are lobbying to import CBD-rich cannabis strains from Colorado, say they will keep up their campaign. "This changes nothing" in regard to children being able to access CBD, said Jennifer May, mother of 11-year-old Stockton, who suffers from Dravet syndrome. "On the other hand, it does lend credibility to the potential of CBD as a treatment." Like many Dravet patients, Stockton has tried dozens of pharmaceutical fixes, and run out of options. He can no longer use the toilet and has to be fed from a tube. "Orphan drug" designation qualifies GW for tax credits and exclusive rights to the drug if approved. But FDA approval for Epidiolex could take a year or more. (Salt Lake Tribune, Nov. 18)

Israel has the world's highest proportion of registered medical marijuana users—but the program has been kept under tight control of the Health Ministry. Now, Israel's parliament, the Knesset, is set to vote on a bill that would allow private physicians to prescribe cannabis for their patients. Health Minister Yael German opposes the measure, making the usual argument that it would open the floodgates of recreational use: "It would not be unrealistic to assume that there would be patients who would pressure doctors to write them a cannabis prescription for any bump, headache or toothache."

The US Supreme Court on Oct. 7 rejected a challenge to the federal government's classification of cannabis as a Schedule I drug with no legitimate medical use. Challenger Americans for Safe Access contended that more than 200 studies have established that cannabis is safe and effective in relieving pain and nausea, and in relieving the effects of chemotherapy, among other medical uses. But federal courts have let stand the Drug Enforcement Administration's stance that the studies are insufficient.